IWP-121: a novel sGC stimulator that reduces blood pressure and exhibits anti-fibrotic and anti-inflammatory activities in the Dahl Salt-Sensitive rat model by unknown
MEETING ABSTRACT Open Access
IWP-121: a novel sGC stimulator that reduces
blood pressure and exhibits anti-fibrotic and
anti-inflammatory activities in the Dahl
Salt-Sensitive rat model
Courtney Shea*, Sheila Ranganath, Guang Liu, Derek Wachtel, Peter Germano, Jenny Tobin, Ping Zhang,
Samuel Rivers, G-Yoon Jamie Im, James Sheppeck II, Jaime Masferrer
From 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications
Trier, Germany. 19-21 June 2015
Background
Soluble guanylate cyclase (sGC) is an intracellular receptor
that can be activated by nitric oxide (NO) and sGC stimu-
lators to produce cyclic guanosine monophosphate
(cGMP), thereby modulating a number of downstream
cellular and physiological responses including phosphory-
lation of VASP and vasodilation. In the Dahl Salt-Sensitive
(DSS) rat model of hypertension, cGMP production by
sGC is decreased, most likely due to reactive oxygen
species (ROS) converting NO to peroxynitrite, resulting in
depleted pools of NO available to bind to sGC. In this
study we evaluated the efficacy of a novel sGC stimulator
(IWP-121) in the DSS model. Male DSS rats (230-270
grams) received high-salt diet (8% NaCl) for 2 weeks fol-
lowed by high salt plus compound for 6 additional weeks.
IWP-121 was administered at doses of 1, 3, and 10 mg/kg/
day in the chow (n=8/group). Losartan (30 mg/kg/day in
the water) was used as a positive control, in addition to
both High Salt (HS) and Normal Salt (NS). All groups
were compared to HS control group for analyses.
IWP-121 dose dependently decreased mean blood
pressure (MAP) throughout the study. Additionally,
IWP-121 (at all doses tested) and losartan had statisti-
cally significant effects on decreasing heart hypertrophy
and plasma NT-proBNP but only IWP-121 had an effect
on attenuating liver hypertrophy. IWP-121 decreased
microalbuminuria (an indicator of kidney end organ
damage) as well as attenuated serum biomarkers known
to be involved in inflammatory and fibrotic processes.
Conclusion
In the rat DSS model of hypertension, there is a decrease
in cGMP levels most likely due to the inactivation of
endogenous NO by ROS. The sGC stimulator IWP-121,
when administered in the diet exhibited sustained dose-
dependent reduction in blood pressure. Additionally,
IWP-121 attenuated heart and liver hypertrophy and
reduced NT-proBNP, a biomarker of heart failure. The
compound reduced levels of biomarkers for inflammation
and fibrosis, and demonstrated renal end organ protection.
sGC stimulators, like IWP-121 may have broad therapeu-
tic application by modulating multiple relevant therapeutic
endpoints including blood pressure, hypertrophy, inflam-
mation, and fibrosis.
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